Becton Dickinson and (NYSE:BDX) Price Target Raised to $261.00 at Morgan Stanley

Becton Dickinson and (NYSE:BDX) had its price target boosted by Morgan Stanley from $250.00 to $261.00 in a research note issued to investors on Tuesday morning, BenzingaRatingsTable reports. The firm currently has an equal weight rating on the medical instruments supplier’s stock.

A number of other equities research analysts also recently issued reports on the stock. BMO Capital Markets increased their target price on shares of Sun Life Financial from C$58.00 to C$60.00 in a research report on Friday, May 10th. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Wells Fargo & Co cut their target price on shares of Nevro from $75.00 to $70.00 and set an outperform rating for the company in a research report on Monday, May 13th. KeyCorp increased their target price on shares of Harsco from $30.00 to $35.00 and gave the stock an overweight rating in a research report on Friday, May 10th. Finally, Barclays downgraded shares of Buckeye Partners from an overweight rating to an equal weight rating in a research report on Monday, May 13th. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $263.58.

BDX stock opened at $253.83 on Tuesday. Becton Dickinson and has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The stock has a market cap of $67.93 billion, a P/E ratio of 23.05, a price-to-earnings-growth ratio of 1.86 and a beta of 1.12. The business has a 50 day moving average of $245.11.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter in the prior year, the firm earned $2.65 EPS. The company’s revenue was down .6% compared to the same quarter last year. As a group, analysts expect that Becton Dickinson and will post 11.69 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 7th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.21%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

In other news, EVP Samrat S. Khichi sold 16,085 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the transaction, the executive vice president now owns 12,608 shares in the company, valued at approximately $2,958,845.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Simon D. Campion sold 2,903 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total transaction of $687,836.82. Following the transaction, the executive vice president now owns 9,408 shares in the company, valued at approximately $2,229,131.52. The disclosure for this sale can be found here. Insiders have sold a total of 21,154 shares of company stock worth $4,955,775 in the last 90 days. 0.12% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Duality Advisers LP raised its holdings in Becton Dickinson and by 12.7% in the 1st quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock worth $4,365,000 after acquiring an additional 1,970 shares during the period. Meridian Wealth Advisors LLC raised its holdings in Becton Dickinson and by 2.7% in the 1st quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock worth $946,000 after acquiring an additional 99 shares during the period. Pratt Collard Advisory Partners LLC raised its holdings in Becton Dickinson and by 5.1% in the 1st quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock worth $519,000 after acquiring an additional 100 shares during the period. Investec Asset Management North America Inc. raised its holdings in Becton Dickinson and by 5.1% in the 1st quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock worth $2,778,000 after acquiring an additional 543 shares during the period. Finally, British Airways Pensions Investment Management Ltd raised its holdings in Becton Dickinson and by 10.3% in the 1st quarter. British Airways Pensions Investment Management Ltd now owns 87,805 shares of the medical instruments supplier’s stock worth $21,928,000 after acquiring an additional 8,207 shares during the period. Institutional investors and hedge funds own 84.54% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: How is a price target determined?

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.